← stocks-llm Find companies like IBRX →

IMMUNITYBIO INC (IBRX)

Health Care · Cancer cell therapy and immunotherapy · NASDAQ

ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to harness the immune system against cancer and infectious diseases.

View SEC filings Website Yahoo Finance Find companies like IBRX → Ask about IBRX →

What IMMUNITYBIO INC does

ImmunityBio is a clinical-stage oncology and cell therapy company developing cancer immunotherapies and cell-based treatments designed to activate and enhance the immune system. The company's lead approved product is ANKTIVA for non-muscle-invasive bladder cancer and non-small cell lung cancer, supported by a platform called Cancer BioShield that comprises multiple therapeutic modalities including NK-CAR therapies, natural killer cell therapies, and DNA/protein vaccines. The company is advancing a pipeline of next-generation therapies including haNK, taNK, NK-CAR (t-haNK), MSC, and M-ceNK candidates targeting multiple cancer types and infectious diseases.

Themes: ["cancer immunotherapy","natural killer cell therapy","CAR-NK cell therapy","cell therapy manufacturing","bladder cancer treatment","non-small cell lung cancer","cancer vaccines","immune activation"]

Fundamentals

Ask why IBRX looks like this →

Key risks (from latest filing)

["ANKTIVA commercialization risk: company must successfully commercialize its approved product globally across multiple indications (NMIBC, NSCLC) while facing regulatory uncertainties including FDA feedback on supplemental applications for new indications that may require additional clinical trials","Regulatory and R&D execution risk: advanced development of pipeline candidates (NK-CAR, haNK, M-ceNK) depends on successful clinical trial design, patient enrollment, and regulatory approval pathways; delays or failures could significantly impact product development timelines","Financing and capital requirements: company is unprofitable with 351% revenue growth but negative 606% net margin, requiring significant additional capital to fund operations, commercialization, and product development while managing obligations under related-party financing arrangements (RIPA)"]

See IBRX's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.